Drug Trial Radar · NCT02431247
A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects
Last checked: Nov 19, 2026Latest source record: Sep 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
725
Actual
Start
Jul 6, 2015
Primary completion
Mar 2, 2017
Study completion Sep 30, 2020
Sponsor
- Lead sponsor
- Janssen Sciences Ireland UCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Apr 30, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to demonstrate non-inferiority in efficacy of a darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed dose combination (FDC) tablet versus Darunavir/Cobicistat (DRV/COBI) FDC coadministered with Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) FDC in human immunodeficiency virus-1 (HIV-1) infected, antiretroviral (ARV) treatment naive adult participants.
Conditions
- Immunodeficiency Virus Type 1, Human
Interventions
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDCDrug
A tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF) 10 mg will be administered once daily.
DRV/COBI FDCDrug
A tablet containing DRV 800 mg and COBI 150 mg will be administered once daily.
FTC/TDF FDCDrug
A tablet containing FTC 200 mg and TDF 300 mg will be administered once daily.
D/C/F/TAF FDC - Matching PlaceboDrug
Matching placebo of D/C/F/TAF FDC will be administered once daily.
FTC/TDF FDC Matching PlaceboDrug
Matching placebo of FTC/TDF FDC will be administered once daily.
DRV/COBI FDC Matching PlaceboDrug
Matching placebo of DRV/COBI FDC will be administered once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) Less Than (<) 50 Copies Per Milliliter (Copies Per mL) (Virologic Response) at Week 48 Defined by Food and Drug Administration (FDA) Snapshot ApproachTime frame: At Week 48
Locations
80 sites in 10 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Phoenix, Arizona
Site not named
Bakersfield, California
Site not named
Long Beach, California
Site not named
Los Angeles, California
Site not named
North Hollywood, California
Site not named
San Francisco, California
Site not named
Washington D.C., District of Columbia
Site not named
Ft. Pierce, Florida
Site not named
Miami, Florida
Site not named
Orlando, Florida
Site not named
West Palm Beach, Florida
Site not named
Savannah, Georgia
Site not named
Boston, Massachusetts
Site not named
Springfield, Massachusetts
Site not named
Berkley, Michigan
Site not named
Minneapolis, Minnesota
Site not named
St Louis, Missouri
Site not named
Hillsborough, New Jersey
Site not named
Newark, New Jersey
Site not named
Somers Point, New Jersey
Site not named
Santa Fe, New Mexico
Site not named
Manhasset, New York
Site not named
Chapel Hill, North Carolina
Site not named
Winston-Salem, North Carolina
Site not named
Cincinnati, Ohio
Site not named
Fort Worth, Texas
Site not named
Houston, Texas
Site not named
Seattle, Washington
Site not named
Antwerp, Belgium
Site not named
Brussels, Belgium
Site not named
Ghent, Belgium
Site not named
Toronto, Ontario, Canada
Site not named
Montreal, Quebec, Canada
Site not named
Clamart, France
Site not named
Le Kremlin-Bicêtre, France
Site not named
Lyon, France
Site not named
Marseille, France
Site not named
Montpellier, France
Site not named
Nantes, France
Showing 40 of 80 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.